The Latest Cardiac and Vascular News
Results Suggest Highly Effective Method to Treat Ventricular Tachycardia, a Leading Cause of Sudden Cardiac Death WALTHAM, Mass.–(BUSINESS WIRE)–Thermedical®, a developer of thermal-ablation systems to treat ventricular tachycardia (VT), announced that results from a First-in-Human Early Feasibility Study (EFS) using the new Durablate® catheter to treat VT were presented in […]
Results presented virtually via Heart Rhythm 365 Platform; study met primary effectiveness endpoint of superiority in favor of the hybrid Convergent procedure MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the results from the CONVERGE […]
Company initiates development of CLBS119 for the repair of COVID-19 induced lung damage and expands its proprietary CD34+ cell therapy portfolio Adds ~$16 million in funding bringing current cash to ~$34 million Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. , May 07, 2020 (GLOBE NEWSWIRE) […]
– Strategic investments round out $9.2M Series B round of financing – Sajid Malhotra joins Genetesis Board of Directors MASON, Ohio, May 7, 2020 /PRNewswire/ — Genetesis Inc, a medical technology company that has developed non-invasive, biomagnetic CardioFlux™ imaging, today announced several important updates. The company has closed significant strategic investments from TDK […]
Study Shows Accuracy of Deep Learning in Interpreting Multiple Levels of Remote Cardiac Monitoring Data MINNEAPOLIS, May 7, 2020 /PRNewswire/ — Preventice Solutions announced the publication of real-world data further validating BeatLogic® deep learning models designed to detect and classify multiple levels of data on heart rhythms gathered using BodyGuardian® remote cardiac monitoring […]
U.S. FDA Special Protocol Assessment agreement for PRECISION-AF, a single pivotal Phase 3 clinical trial of genetically targeted Gencaro PRECISION-AF trial to evaluate Gencaro as a potential treatment for prevention of atrial fibrillation in a heart failure population for which there are no FDA indicated drug therapies PRECISION-AF clinical trial […]
Top-line Results for GALACTIC-HF Expected in Q4 2020 Ended Q1 with More Than Two Years of Going Forward Cash Based on 2020 Guidance SOUTH SAN FRANCISCO, Calif., May 06, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first quarter of 2020. Net loss for the […]
New data provide additional evidence of efficacy for Gencaro compared to active control in a pharmacogenetically-defined HF population at risk for AF recurrence ° 26% reduction in total time spent in AF (p < 0.001) ° 30% decrease in AF interventions and cardiovascular adverse events (p = 0.008) ° 55% lower incidence […]
BRISBANE, Calif., May 06, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the first quarter ended March 31, 2020. “Our team has continued to drive toward our mission, despite the extraordinary personal and professional disruptions introduced by the COVID-19 pandemic. The progress made has been […]
ANDOVER, Mass., May 06, 2020 (GLOBE NEWSWIRE) — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended March 31, 2020. “We began 2020 with strong momentum […]
